Background: Stage is a critical determinant of treatment among endometrial carcinoma patients; understanding patterns of tumor spread may suggest approaches to improve staging. Specifically, the importance of exfoliation of endometrial carcinoma cells through the fallopian tubes into the peritoneum is ill defined. We assessed the hypothesis that tubal ligation (TL), which should impede transtubal passage of cells, is associated with lower endometrial carcinoma stage at presentation and, consequently, lower mortality.
article staging procedures and consequently lead to better management (2) .
Endometrial cancers can metastasize via lymphatics, blood vessels, invasion through the uterine wall, or exfoliation through the fallopian tube into the peritoneal cavity; however, the clinical importance of the last of these routes is poorly defined (3) (4) (5) (6) (7) (8) (9) . Moreover, the fallopian tube may represent a gateway to the peritoneum for both true metastases and potentially inconsequential dislodgement of cells consequent to medical interventions. An analysis of 262 endometrial cancers, oversampled for aggressive tumor subtypes, found that tumor cells were identifiable within the fallopian tube lumen in 26.1% of high-grade cases and that their presence was associated with peritoneal metastases (9) . Intraluminal tumor cells were found among only 2.8% of low-grade endometrial cancers. In contrast, a meta-analysis concluded that hysteroscopy is associated with a statistically significant increase in positive peritoneal cytology, but not with worse prognosis, suggesting that uterine insufflation during the procedure may detach tumor cells that pass through the tubes and reach the peritoneum without worsening clinical outcomes (10) .
Given the strong predominance of indolent endometrial cancer subtypes in most studies (ie, low-grade endometrioid carcinoma), it is unclear whether analyses of the effect of instrumentation on tumor dissemination apply to aggressive endometrial cancer subtypes. Nonetheless, peritoneal cytology seems to lack independent prognostic significance overall and was recently removed from endometrial cancer staging guidelines (10) .
We hypothesized that transtubal spread is an important mechanism of metastasis for aggressive subtypes of endometrial cancer. Therefore, women who develop these tumors following tubal ligation (TL), which should block egress of cells into the peritoneum, would present at lower stages and have lower mortality. A report of 142 serous endometrial carcinomas found that positive peritoneal cytology and stage IV disease were less frequent among women who were status-post TL compared with those who had not undergone the procedure (8) . Unexpectedly, this report found that TL was associated with worse prognosis, possibly attributable to increased nodal metastases. In the present study, we examined associations between TL, endometrial carcinoma stage, extra-uterine metastasis, and mortality in a study of 4489 pathologically well-characterized endometrial carcinoma cases that had been oversampled for aggressive tumor types.
Methods

Study Population
Briefly, the NRG Oncology/Gynecologic Oncology Group (GOG) 210 Trial was conducted from September 22, 2003 to December 1, 2011 at 62 US institutions. Eligible subjects included women with presurgical diagnoses of endometrial carcinoma (carcinoma or carcinosarcoma) who were eligible for surgery and had not undergone prior retroperitoneal surgery or pelvic/abdominal radiation. Prior to surgery (hysterectomy, bilateral salpingooophorectomy, and lymph node sampling), consenting patients completed a self-administered questionnaire that collected demographic and epidemiologic information (11) . Follow-up information on causes of death was available through December 31, 2013. Of 6124 women enrolled, 5492 (89.7%) completed questionnaires. We excluded women on the following bases: incomplete surgical staging (n = 20), final diagnosis not endometrial carcinoma (n = 53), benign diagnoses (n = 6), diagnosis of a second primary (n = 2), misclassified pathologic diagnosis based on central pathology review (n = 49), inadequate material for pathology review (n = 22), protocol deviations (n = 17), and improper preprotocol treatment (n = 1). We excluded cases with missing grade (n = 23), mixed epithelial tumors (n = 556), mucinous tumors (n = 18), unusual histologic types (including squamous cell, undifferentiated, and dedifferentiated histologies) (n = 111), missing stage (n = 5), and unknown history of TL (n = 120), leaving 4489 patients for analysis. This study was approved by institutional review boards at the National Cancer Institute and participating study centers. Women provided informed consent prior to participation.
Tumor Characteristics and Outcome Assessment
Endometrial tumors were classified as low-grade (grades 1 and 2) endometrioid carcinoma, high-grade (grade 3) endometrioid carcinoma, serous carcinoma, clear cell carcinoma, or carcinosarcoma. Depth of myometrial invasion (negative, inner half, outer half, serosa), stage according to International Federation for Gynecology and Obstetrics (FIGO) 1988 criteria (12) , pelvic and aortic lymph node involvement, peritoneal cytology results, and extra-uterine sites of metastasis were recorded. Diagnoses of high-grade endometrioid carcinoma, serous carcinoma, clear cell carcinoma, carcinosarcoma, and tumors involving the cervix or with non-nodal metastases were reviewed centrally.
Tumors showing evidence of mixed histologic subtypes were classified into a separate category. Information on vital status, date, and cause of death were obtained from medical records, supplemented with cancer registry information.
Statistical Analysis
Distributions of tumor subtype, stage, pelvic and aortic lymph node involvement, peritoneal cytology results, and histopathologically diagnosed peritoneal metastasis by TL status were compared by chi-square tests. We also examined the distribution of stage by TL status restricted to endometrial carcinoma cases without myometrial invasion and negative pelvic/aortic lymph nodes with chi-square tests. Multivariable logistic regression models were used to estimate adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for relationships between TL with stage and peritoneal metastasis. For each outcome (stage and peritoneal metastasis), we constructed minimally adjusted models that included TL, age at diagnosis (<55, 55-59, 60-64, 65-69, ≥70 years), ethnicity (white, black, other), education (<high school, high school/GED, some college/technical school, college graduate or beyond), annual income (<$20 000, $20 000-$39 999, $40 000-69 999, ≥$70 000), year of enrollment (2003-2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011) , and tumor subtype (low-grade endometrioid, high-grade endometrioid, serous, carcinosarcoma, clear cell). Variables shown in Supplementary Table 1 (available online) were explored as confounders and retained when inclusion of the factor changed estimates by more than 10% or when the model fit was significantly improved as assessed by the likelihood ratio (LR) test. As a result, the final logistic regression model for stage did not include additional adjustment factors, while the model for peritoneal metastasis additionally included parity (nulliparous, 1-2 live births, ≥3 live births). We then examined tumor subtype as an effect modifier of relationships between TL with stage and peritoneal metastasis by assessing LR tests for models with and without multiplicative interaction terms. We also explored associations between specific extra-uterine sites of metastasis and TL in multivariable logistic regression models.
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We performed exact logistic regression when the sample size in a particular stratum was less than five. Because of the computational burden required in exact logistic regression, these models were only adjusted for age.
Follow-up time was computed from the date of enrollment to date of death or end of follow-up. Kaplan-Meier estimates and logrank tests were used to compare survival distributions according to TL in the overall study population and stratified by tumor subtype and stage. Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals for associations between TL, endometrial carcinoma-specific mortality, and all-cause mortality. Similar to the logistic regression analyses, we assessed the previously mentioned covariates as potential confounders of the relationship between TL and mortality in minimally adjusted models, which also included adjuvant therapy (none, radiotherapy, chemotherapy, radiotherapy and chemotherapy). Oral contraceptive use (no, yes), menopausal hormone use (none, estrogen only, progestin only, estrogen plus progestin), and tamoxifen use (no, yes) improved the model fit and were included in the final models. Initial analyses excluded stage and then were repeated to assess whether differences in mortality by TL status were mediated by stage. Effect modification of the TL-mortality relationship by tumor subtype was assessed by including multiplicative interaction terms between TL and tumor subtype and comparing models with and without the interaction terms and assessing the LR test statistic. The proportional hazards assumption was tested by comparing a model with an interaction term between TL and follow-up time to a model without the interaction term using an LR test. We did not observe a statistically significant violation of proportional hazards. Statistical analyses were performed using SAS software (version 9.3, SAS Institute, Inc.) and LogXact software (version 10, Cytel Inc.). All P values were twosided; statistical significance was set at P values of less than .05.
Results
Study Population
Of the 4489 study participants, 27.6% (n = 1238) reported a previous TL at a median age of 32 years (range = 18 to 59 years). Table 1 . TL was associated with younger age at diagnosis (P < .001), aggressive tumor subtypes (P = .002), absence of myometrial invasion (P = .05), lower stage (P < .001), negative peritoneal cytology (P < .001), and negative peritoneal biopsies (P < .001). TL was also associated with black race, lower educational attainment, lower annual income, three or more live births, current smoking status, and ever use of oral contraceptives (Supplementary Table 1 , available online). The characteristics of women with TL in our study are similar to nationally representative estimates-for example, data from the most recent National Survey on Family Growth show that TL surgery is more common among black compared with white women (32.7% vs 17.7%), more common among women with three or more live births compared with nulliparous women (42.9% vs 0.6%), and more common among women with lower compared with higher income (28.5% with income ≤149% of the poverty level vs 13.5% with income ≥300% of the poverty level) (13) .
Tubal Ligation and Endometrial Tumor Characteristics
Endometrial carcinoma patients who were status-post TL were less likely to present with stage III (OR = 0.63, 95% CI = 0.52 to 0.78) or stage IV (OR = 0.14, 95% CI = 0.08 to 0.24) carcinomas compared with stage I (Table 2) . Heterogeneity by tumor subtype was not observed (P heterogeneity = .46). The inverse association between TL and stage IV disease was evident among all histologic subtypes. Time since TL was not related to endometrial carcinoma stage (data not shown). Among cases with peritoneal tissue sampling, 6.4% showed metastases (Table 3) . TL was inversely significantly associated with peritoneal metastasis overall (OR = 0.39, 95% CI = 0.22 to 0.68) and among high-grade endometrioid (OR = 0.23, 95% CI = 0.04 to 0.79) and serous carcinoma cases (OR = 0.28, 95% CI = 0.11 to 0.68); odds ratios for carcinosarcoma and clear cell were below unity, but not statistically significant based on small numbers. Significant heterogeneity by tumor subtype was not observed (P heterogeneity = .26). TL was also inversely associated with metastasis to fallopian tubes, ovaries, omentum, parametrium, and bladder/bowel mucosa (Supplementary Table 2 , available online).
We also examined the distribution of stage according to TL status among 969 women without myometrial invasion and negative pelvic and aortic lymph nodes. Among 297 women in this subgroup who underwent TL, zero presented with stage IV and 10 (3.4%) presented with stage III tumors compared, with nine stage IV (1.3%) and 27 (4.0%) stage III tumors among 672 women who had not undergone TL (data not tabled).
Tubal Ligation and Mortality
Among 4489 endometrial carcinoma patients with median follow-up of 4.99 years (range: 1 day-9.84 years), there were 831 deaths, of which 570 (68.6%) were ascribed to endometrial carcinoma. Compared with women with intact tubes, women who were status-post TL had lower endometrial carcinoma-specific mortality overall (log-rank P = .04), as well as among serous carcinoma (log-rank P = .02) and clear cell carcinoma cases (logrank P = .03) (Figure 1 ). Associations between TL status and mortality within stage did not show statistically significant differences ( Figure 2 ). We observed similar associations with allcause mortality (data not shown).
Cox models adjusted for covariates except stage demonstrated that TL was inversely associated with endometrial carcinoma-specific mortality (HR = 0.74, 95% CI = 0.61 to 0.91) ( Table 4 ). This result appeared attributable to reduced risk of death for serous carcinoma (HR = 0.69, 95% CI = 0.49 to 0.98) and clear cell carcinoma (HR = 0.19, 95% CI = 0.06 to 0.63), although 
Sensitivity Analyses: Serous Carcinomas
We performed sensitivity analyses to compare our data with a prior report examining TL and mortality among patients with serous carcinomas (8) . In sensitivity analyses restricted to stage III and IV serous carcinomas, we did not observe a relationship between TL and all-cause mortality (HR = 0.78, 95% CI = 0.53 to 1.14). We did not identify differences in lymph node status or number of positive lymph nodes comparing serous carcinoma cases with and without a prior TL. We found a reduced risk of death among TL patients with positive pelvic lymph nodes (n = 138, HR = 0.54, 95% CI = 0.54 to 0.96) but did not find an association between TL and allcause mortality among women with positive aortic nodes (data not tabled). 
Discussion
This analysis demonstrates that women who undergo TL at young ages and develop endometrial carcinoma later in life present with lower-stage disease than women who have not undergone TL, resulting in an improved prognosis for women with serous, carcinosarcoma, and clear cell tumors. The inverse associations between TL, endometrial carcinoma stage, and peritoneal metastasis are consistent with a prior single institution report of 142 serous carcinomas (8) . Interruption of transtubal passage of tumor cells with metastatic potential represents a possible explanation for the improved prognosis related to TL. In the subgroup of women whose tumors did not invade the myometrium or metastasize to lymph nodes (and were therefore unlikely to spread via a lymphohematogenous route), none had stage IV carcinoma and only 1.3% had stage III disease, lending additional support to the favorable effects of TL on stage. In contrast to the prior report (8), we did not find that TL was associated with higher mortality among subsets of serous carcinoma patients. Our data show that among patients with endometrioid carcinomas, TL was associated with a lower assigned stage, but was unrelated to mortality. A prior meta-analysis concluded that hysteroscopy is associated with positive peritoneal cytology but not worse prognosis (10) , suggesting that instrumentation may dislodge tumor cells, which lack metastatic potential. TL could lower assigned stage by blocking transtubal passage of cells into the peritoneum dislodged by instrumentation, but this would not affect mortality if such cells lacked the potential to form peritoneal metastases, which may be true for most low-grade endometrioid carcinomas.
Unlike endometrioid carcinomas, aggressive endometrial carcinoma types, particularly serous carcinomas (14) , may metastasize despite limited tumor volume in the uterus. Notably, "minimal uterine serous carcinoma" (15) , which comprises approximately 20% of serous tumors (14, 16) , has been found to present with extra-uterine disease in up to 45% of women (17) . Further, molecular analysis in these cases suggests that intraand extra-uterine tumor cells are often clonally related (18) (19) (20) (21) . Among 21 endometrial intraepithelial carcinomas associated with concurrent extra-uterine tumor deposits, Jia et al. (18) found identical p53 mutations across foci in 10 cases and overlapping patterns in six cases. None of the 10 cases with identical mutations were found to contain serous tubal intraepithelial carcinomas, but three contained tumor cells in the tubal lumen. We did not systematically examine surgical pathology specimens for intraluminal tumor cells in this study; however, our data indirectly support the hypothesis that transtubal passage of such cells may be a clinically relevant route of metastasis for nonendometrioid tumor subtypes, including tumors without substantial myometrial invasion. Future studies to assess the possible prognostic importance of intraluminal tumor cells for aggressive endometrial carcinoma subtypes may be warranted, analogous to studies that have suggested that lymphovascular invasion affects prognosis among women with high-grade endometrial carcinomas but not low-grade carcinomas (22) . 
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Our findings suggest the hypothesis that endometrial intraepithelial carcinoma, the presumptive precursor of serous endometrial carcinoma, may also represent a source of tumors that are currently classified as ovarian primary tumors (20, 21) . Given that TL reduces spread of serous endometrial carcinomas to the ovaries and peritoneum, we hypothesize that TL reduces the chance that a woman with a widely metastatic serous endometrial carcinoma will be misclassified as having a tubal/ovarian primary. Interestingly, black women have a higher frequency of TL and higher reported incidence rate of serous endometrial carcinomas than white women (23, 24) , who conversely, have a higher reported incidence rate of tubal/ovarian high-grade serous tumors (25, 26) .
Strengths of our study include the large overall sample size with representation of uncommon aggressive tumors, central pathology review (apart from cases originally diagnosed as endometrioid carcinoma grade 1 or 2), and multivariable modeling with adjustment for potential confounders. Our study also has limitations, including lack of information regarding type of TL procedure, which has evolved over time. The extent to which newly introduced methods of fallopian tube disruption, such as mechanical clips or tubal implants, could prevent passage of endometrial tumor cells is unknown. Partial excision of tubal segments likely represents the majority of procedures, especially for women enrolled in the early years of the trial (27) . In addition, some of our tumor subtype-specific analyses were hindered by low numbers, which resulted in the use of computationally burdensome analyses, which were not adjusted for all confounders. Further, given our hypothesis-driven analysis approach, we did not formally adjust for multiple comparisons. However, we noted that our findings for serous and carcinosarcoma tumors would remain statistically significant after a Bonferroni correction was applied.
In conclusion, our study provides evidence that transtubal spread is an important mechanism of metastasis for aggressive histological types of endometrial carcinoma and that this process can be inhibited by TL. As a corollary, the endometrium should be considered a potential source of high-grade serous carcinomas that present with pelvic disease, especially when examination of tubes is negative for in situ lesions and ovaries show multiple nodules, consistent with secondary involvement. Our data are also consistent with the proposal that the tubes may represent a conduit for mechanical dislodgement of endometrioid carcinoma cells, which may lead to positive peritoneal washes, but lack prognostic significance. Lesions resembling in situ carcinoma of the fallopian tube have been associated with endometrial intraepithelial carcinoma, the presumed precursor of serous endometrial carcinoma, and with endometrial carcinoma (5, (28) (29) (30) , but whether such lesions are independent or inter-related is unknown. Comprehensive mapping of the tubes, endometrium, and ovaries may help define the site of origin of cancers of the pelvis and determine whether clinical behavior varies by primary site. These studies could assess the tube both as a source of serous carcinoma and a conduit for spread, which could have implications for staging, management, and understanding of the pathogenesis of these tumors.
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